GET DAILY SIGNALSWhy Is Biodesix (BDSX) Stock Down -44.30% Today?
Key Takeaways
- BDSX shares plunged roughly 44.30% on November 6, falling to about $11.05 from a prior close of $19.84.
- The primary catalyst was third-quarter 2026 results that missed revenue expectations, paired with a sharp cut to full-year guidance.
- Revenue growth decelerated to 10% year over year, a steep slowdown from 42% in the first quarter and 34% in the second quarter.
- Management cited salesforce attrition, heavier-than-expected primary care seasonality, and delayed development-services projects as key headwinds.
- Analysts responded by trimming price targets, with TD Cowen lowering its target to $34 from $40 while maintaining a Buy rating.
- Traders are now watching whether the company can rebuild its salesforce and whether October's momentum in new physician acquisitions translates into a fourth-quarter rebound.
- For deeper insight into Price Targets, Earnings, and Forecast data, explore Tickeron's dedicated pages for additional research.
- To discover AI-driven trading strategies across thousands of tickers, visit the Trending AI Robots section.
Opening Summary
Biodesix, Inc. (BDSX), a Colorado-based diagnostics company that develops blood-based tests for lung disease, including its Nodify Lung testing portfolio, saw its stock plummet on November 6. Shares traded near $11.05, down approximately 44.30% from the prior session's close of $19.84. The decline extends a selloff that began after the company reported third-quarter results following the November 5 close, with markets reacting to a revenue shortfall and, more importantly, a meaningful reduction in full-year revenue guidance.
Q3 Results Miss and Full-Year Guidance Cut
The dominant driver behind the move was a disappointing third-quarter earnings release. Biodesix reported a net loss of $0.75 per share on revenue of $24.04 million, missing consensus revenue estimates of roughly $27.25 million by about 11.8%. While the bottom-line loss was roughly in line with expectations, the top-line shortfall broke the company's streak of beat-and-raise quarters that had underpinned its earlier valuation.
Most damaging to sentiment was the revised outlook. Management lowered full-year 2026 revenue guidance to a range of $101 million to $103 million, down from a prior range of $108 million to $114 million. That new range sits below even the original guidance issued at the start of the year, signaling that the slowdown is more than a one-quarter issue. The guidance reset reframed the growth narrative from a high-growth diagnostics story to one grappling with execution and timing challenges.
Slowing Growth and Salesforce Turnover
Beneath the headline numbers, the deceleration was stark. Total revenue growth slowed to 10% year over year, down from 42% in the first quarter and 34% in the second. Diagnostic Testing revenue rose 16%, while Development Services revenue fell to $1.0 million from $1.9 million a year earlier as project starts were delayed by external customer dependencies.
Management attributed part of the miss to salesforce attrition, noting that average productive sales representatives declined to 101 from 104 amid turnover and competitive poaching. The company also cited heavier-than-expected primary care seasonality and pushed some services work into 2027. Although gross margin held at 81%, the combination of stalled top-line growth and a shrinking forward outlook gave investors limited reason to defend the stock.
Analyst Reaction
The earnings-driven move was reinforced by a swift adjustment in sell-side expectations. TD Cowen lowered its price target on BDSX to $34 from $40, citing salesforce turnover and seasonality that weighed on results, while maintaining a Buy rating. The cautious tone of these revisions added to the pressure on a stock that had already posted substantial gains earlier in the year.
Market Context and Trading Activity
Trading activity was exceptionally heavy relative to the stock's typical volume, reflecting the scale of the repricing. The stock traded down roughly 40% in premarket action before extending losses into the regular session, indicating sustained selling rather than a single flush. The move was idiosyncratic rather than sector-driven: the decline reflected company-specific fundamentals, as the broader medical diagnostics space did not experience a comparable selloff, and the shares' prior momentum had made them especially vulnerable to a guidance cut.
What Comes Next for BDSX
Investors will now focus on whether Biodesix can stabilize its sales organization and convert October's reported strength in new physician acquisition into renewed test-volume growth. The company expects only about $1 million in Development Services revenue in the fourth quarter, with some work slipping into 2027, adding uncertainty to near-term results. The adjusted outlook implies a marked slowdown in fourth-quarter lung diagnostics growth, and any further erosion in salesforce productivity or test volumes could extend the pressure. Conversely, the company's pipeline, including its lung nodule framework and molecular residual disease programs, remains a longer-term source of potential upside.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of these bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and the symbols they trade. Only the top performers are featured in the Trending AI Robots section. Explore the page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for BDSX turns negative, indicating new downward trend
BDSX saw its Momentum Indicator move below the 0 level on October 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In 79 of the 86 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for BDSX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 43 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDSX moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BDSX crossed bearishly below the 50-day moving average on October 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BDSX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for BDSX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +12.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BDSX advanced for three days, in 202 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
BDSX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BDSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.843) is normal, around the industry mean (65.710). P/E Ratio (-2.752) is within average values for comparable stocks, (4.185). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.463) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalSpecialties
Advertisement